Moving Beyond Known Targets – Conversation With CEO Lidia Pieri, Sibylla Biotech

By Jonas Mortensen, CEO, BioBridge Solutions

For decades, biomedical research has concentrated on a limited subset of human proteins, leaving many disease‑driving targets classified as “undruggable.” This interview examines the scientific and conceptual shifts challenging that long‑standing assumption.

Beyond technical advances, the discussion offers an unfiltered view of biotech leadership—navigating uncertainty, managing expectations, and balancing ambitious vision with disciplined execution. It explores entrepreneurship, the transition from academia to industry, and the human dimensions of building resilient teams in a high‑risk environment.

The conversation highlights how intellectual curiosity, data‑driven rigor, and a willingness to move beyond established boundaries are expanding the scope of drug discovery and opening new possibilities for patients who currently lack effective therapeutic options.